The engagement with Alacrita Consulting is expected to aid in the expansion of the use of TAAP and MPAR®, as well as the rapid development and commercialization of Ensysce's next generation opioids. This could potentially lead to increased revenues for the company, which may positively impact its stock price in the short term.